TrialBlood advances2020

Phase 2 multiple-dose study of an FcRn inhibitor, rozanolixizumab, in patients with primary immune thrombocytopenia.

Tadeusz Robak et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.